Recombinant Mouse LILRC1 Protein, CF

When Recombinant Mouse LILRC1 (Catalog # 9288-T4) is coatedat 2 µg/mL, Recombinant Human Angiopoietin-likeProtein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 =60-360 ng/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse LILRC1 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse LILRC1 (Catalog # 9288-T4) is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED₅₀ = 60-360 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse LILRC1 protein
  Gln17-Asn248, with a C-terminal 6-His tag
• Accession #: AAY44811.1
• N-terminal Sequence: No results obtained. Gln17 inferred from enzymatic pyroglutamate treatment revealing Glu18
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 27 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 36-50 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse LILRC1 Protein, CF

• E030017K20;EG232801;Gm4878;Lilra5
• LILRA5
• LILRC1

Background

The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs) (1). Mouse LILRC1 (leukocyte immunoglobulin-like receptor C1), also known as LILRA5, ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail (2, 3). The ECD contains two Ig-like domains (4), and the transmembrane segment contains a positively charged aspartic acid residue which may mediate its association with the signaling molecule, FcR common gamma chain (3, 5). Within the ECD, mouse LILRC1/LILRA5 shares 56% and 85% aa sequence identity with human and rat LILRA5, respectively. LILRA5 is expressed by monocytes, macrophages, and neutrophils (2, 3, 5). It is found as an approximately 40 kDa molecule on the cell surface, while a soluble 25 kDa form can be released into the synovial fluid of rheumatoid arthritis patients (2, 5). Cross-linking of LILRA5 on monocytes induces the expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) as well as the anti-inflammatory IL-10 (2, 5). R&D Systems in-house testing indicates that LILRC1/LILRA5 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (6).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Borges, L. et al. (2003) Blood 101:1484.
3. Hoelsbrekken, S.E. et al. (2005) Immunogenetics 57:479.
4. Shiroishi, M. et al. (2006) J. Biol. Chem. 281:19536.
5. Mitchell, A. et al. (2008) Eur. J. Immunol. 38:3459.
6. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Uniprot:
  • AAY44811.1()